| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1998;66:1876-1883
© 1998 The Society of Thoracic Surgeons
a Department of Surgery, Creighton University, Omaha, Nebraska, USA
b The Crump Institute for Biological Imaging and Department of Molecular and Medical Pharmacology, Division of Nuclear Medicine, and Department of Biomathematics, University of California Los Angeles School of Medicine, Los Angeles, California, USA
Address reprint requests to Dr Gambhir, Crump Institute for Biological Imaging, UCLA School of Medicine, A-222B JLNRC, 700 Westwood Plaza, Box 951770, Los Angeles, CA 90095-1770
e-mail: (sgambhir{at}mednet.ucla.edu, wscott@creighton.edu)
Presented at the Thirty-fourth Annual Meeting of The Society of Thoracic Surgeons, New Orleans, LA, Jan 26–28, 1998.
Background. Preliminary studies have shown that thoracic positron emission tomography (PET) is more accurate than thoracic computed tomography (CT) for the staging of non–small cell lung carcinoma. In the present study the cost-effectiveness, as measured by national Medicare reimbursed costs, and patient life expectancy are used to compare several thoracic PET-based strategies with a conventional thoracic CT-based strategy for preoperative staging.
Methods. Five decision strategies for selection of potential surgical candidates were compared; thoracic CT alone or four different strategies that use thoracic CT plus thoracic PET. The various paths of each strategy are dependent on numerous variables that were determined from a review of the medical literature. Life expectancy was calculated using the declining exponential approximation of life expectancy and reduced on the basis of procedural morbidity and mortality. Costs were based on national Medicare reimbursed costs. For all possible outcomes of each strategy, the expected cost and projected life expectancy were determined. The effects of changing one or more variables on the expected cost and life expectancy were studied using sensitivity analysis.
Results. A strategy that uses PET only after a negative CT study is shown to be a cost-effective alternative to the CT-alone strategy ($25,286 per life-year saved).
Conclusions. These results show through rigorous decision tree analysis the potential cost-effectiveness of using thoracic PET in the management of non–small cell lung carcinoma. Greater use of thoracic PET for non–small cell lung carcinoma staging is warranted, and further clinical trials should help to validate the analytic results predicted from this study.
Related Article
Ann. Thorac. Surg. 1998 66: 1884-1885.
This article has been cited by other articles:
|
|
 |
|
  H. K. Mohan and K. A. Miles Cost-Effectiveness of 99mTc-Sestamibi in Predicting Response to Chemotherapy in Patients with Lung Cancer: Systematic Review and Meta-Analysis J. Nucl. Med., March 1, 2009; 50(3): 376 - 381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. A. Margolis, J. M. Hoffman, R. J. Herfkens, R. B. Jeffrey, A. Quon, and S. S. Gambhir Molecular Imaging Techniques in Body Imaging Radiology, November 1, 2007; 245(2): 333 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Silvestri, M. K. Gould, M. L. Margolis, L. T. Tanoue, D. McCrory, E. Toloza, and F. Detterbeck Noninvasive Staging of Non-small Cell Lung Cancer: ACCP Evidenced-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 178S - 201S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Bunyaviroch and R. E. Coleman PET Evaluation of Lung Cancer J. Nucl. Med., March 1, 2006; 47(3): 451 - 469. [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Earle Outcomes Research in Lung Cancer J Natl Cancer Inst Monographs, October 1, 2004; 2004(33): 56 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. F. Kelly, T. Tran, A. Holmstrom, J. Murar, and R. J. Segurola Jr Accuracy and Cost-Effectiveness of [18F]-2-Fluoro-Deoxy-D-Glucose-Positron Emission Tomography Scan in Potentially Resectable Non-small Cell Lung Cancer Chest, April 1, 2004; 125(4): 1413 - 1423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker Jr, J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi, et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003 J. Clin. Oncol., January 15, 2004; 22(2): 330 - 353. [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Gould, W. G. Kuschner, C. E. Rydzak, C. C. Maclean, A. N. Demas, H. Shigemitsu, J. K. Chan, and D. K. Owens Test Performance of Positron Emission Tomography and Computed Tomography for Mediastinal Staging in Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis Ann Intern Med, December 2, 2003; 139(11): 879 - 892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Deyo and J. J. Jarvik New Diagnostic Tests: Breakthrough Approaches or Expensive Add-ons? Ann Intern Med, December 2, 2003; 139(11): 950 - 951. [Full Text] [PDF]
|
|
|
|
 |
|
 G. V. Gonzalez-Stawinski, A. Lemaire, F. Merchant, E. O'Halloran, R. E. Coleman, D. H. Harpole, and T. A. D'Amico A comparative analysis of positron emission tomography and mediastinoscopy in staging non-small cell lung cancer J. Thorac. Cardiovasc. Surg., December 1, 2003; 126(6): 1900 - 1904. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. W. Fosko, W. Hu, T. F. Cook, and V. J. Lowe Positron Emission Tomography for Basal Cell Carcinoma of the Head and Neck Arch Dermatol, September 1, 2003; 139(9): 1141 - 1146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Berger, M. K. Gould, and P. G. Barnett The Cost of Positron Emission Tomography in Six United States Veterans Affairs Hospitals and Two Academic Medical Centers Am. J. Roentgenol., August 1, 2003; 181(2): 359 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. LeBlanc, R. Espada, and G. Ergun Non-small Cell Lung Cancer Staging Techniques and Endoscopic Ultrasound: Tissue Is Still the Issue Chest, May 1, 2003; 123(5): 1718 - 1725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Stevens, P. F.A. Bakker, N. J.J. Schlosser, P. P. van Rijk, and J. M.H. de Klerk Use of a Dual-Head Coincidence Camera and 18F-FDG for Detection and Nodal Staging of Non-Small Cell Lung Cancer: Accuracy as Determined by 2 Independent Observers J. Nucl. Med., March 1, 2003; 44(3): 336 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Spiro and J. C. Porter Lung Cancer--Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1166 - 1196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M N Maisey Overview of clinical PET Br. J. Radiol., November 1, 2002; 75(90009): S1 - 5. [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. D'Amico, T. Z. Wong, D. H. Harpole, S. D. Brown, and R. E. Coleman Impact of computed tomography-positron emission tomography fusion in staging patients with thoracic malignancies Ann. Thorac. Surg., July 1, 2002; 74(1): 160 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A G Pitman, R J Hicks, D S Binns, R E Ware, V Kalff, A F McKenzie, D L Ball, and M P MacManus Performance of sodium iodide based 18F-fluorodeoxyglucose positron emission tomography in the characterization of indeterminate pulmonary nodules or masses Br. J. Radiol., February 1, 2002; 75(890): 114 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. F. Esnaola, S. N. Lazarides, S. J. Mentzer, and K. M. Kuntz Outcomes and Cost-Effectiveness of Alternative Staging Strategies for Non-Small-Cell Lung Cancer J. Clin. Oncol., January 1, 2002; 20(1): 263 - 273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S F Barrington Whole body applications of positron emission tomography in oncology Imaging, September 1, 2001; 13(3): 185 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Tucker, M. Coel, J. Ko, P. Morris, G. Druger, and P. McGuigan Impact of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography on Patient Management: First Year's Experience in a Clinical Center J. Clin. Oncol., May 1, 2001; 19(9): 2504 - 2508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.F. Vansteenkiste and S.G. Stroobants The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology Eur. Respir. J., April 1, 2001; 17(4): 802 - 820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Kalff, R. J. Hicks, M. P. MacManus, D. S. Binns, A. F. McKenzie, R. E. Ware, A. Hogg, and D. L. Ball Clinical Impact of 18F Fluorodeoxyglucose Positron Emission Tomography in Patients With Non-Small-Cell Lung Cancer: A Prospective Study J. Clin. Oncol., January 1, 2001; 19(1): 111 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Bousson, J.-L. Moretti, P. Weinmann, N. Safi, F. Tamgac, C. Groiselle, V. de Beco, Y. Hillali, D. Valeyre, and J.-L. Breau Assessment of Malignancy in Pulmonary Lesions: FDG Dual-Head Coincidence Gamma Camera Imaging in Association with Serum Tumor Marker Measurement J. Nucl. Med., November 1, 2000; 41(11): 1801 - 1807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Dhital, C. A.B. Saunders, P. T. Seed, M. J. O'Doherty, and J. Dussek [18F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer Eur. J. Cardiothorac. Surg., October 1, 2000; 18(4): 425 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. F. Patz Jr 1999 Plenary Session: Friday Imaging Symposium : Evaluation of Focal Pulmonary Abnormalities with FDG PET RadioGraphics, July 1, 2000; 20(4): 1182 - 1185. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Farrell, H. P. McAdams, J. E. Herndon, and E. F. Patz Jr Non-Small Cell Lung Cancer: FDG PET for Nodal Staging in Patients with Stage I Disease Radiology, June 1, 2000; 215(3): 886 - 890. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
